AMC Stock Rises 13.6% in a Month: Can the Rally Keep Its Momentum?

AMC's Q2 2026 revenue rose 14.2% year over year to $1.597 billion, 5.8% above consensus, while adjusted EPS of $0.14 beat the $0.01 estimate and adjusted EBITDA surged 69.6% to $321.4 million. Global attendance increased 13.5% to 71.3 million and EBITDA margin expanded 650bps to 20.1%, supporting the stock's 13.6% gain over the past month. However, leverage remains above 6.5x versus a roughly 3x long-term target, and shareholder dilution plus seasonally variable free cash flow could limit further upside.

Analysis

AMC's operating leverage is real, but equity holders capture it only after a heavily levered capital structure absorbs the benefit. At roughly 6.5x leverage, even a modest box-office or concession-margin miss can redirect incremental EBITDA to creditors and force another dilutive liability-management exercise. The market is likely to reward near-term estimate revisions over the next 1-3 months, but a durable rerating requires evidence that free cash flow remains positive through weaker seasonal quarters and that share count stops expanding.

CNK is the cleaner way to express a theatrical recovery: its lower financial risk should permit a greater portion of incremental industry revenue to accrue to equity, while AMC must prioritize deleveraging. A long CNK/short AMC pair isolates the attendance recovery while monetizing AMC's refinancing and dilution overhang; AMC's higher beta can outperform only if the release slate produces sustained upside surprises. IMAX is a differentiated secondary beneficiary because premium-format penetration raises exhibitor revenue per patron without requiring a proportional increase in theater labor or occupancy costs.

The contrarian point is that the recovery may already be reflected in headline EBITDA growth because the comparison period was depressed and fixed-cost absorption creates unusually favorable early-cycle margins. The key 6-18 month question is whether studios maintain a theatrical window and volume sufficient to fill weekdays, rather than concentrating demand into a handful of event releases. Watch domestic box-office trends versus 2019, AMC net debt/share count, and any renewed use of equity issuance; deterioration in any of these would invalidate a fundamental long case.

Key Decisions for Investors

• Prefer long CNK over AMC for a 3-6 month recovery allocation; CNK offers cleaner equity sensitivity to admissions and pricing with materially less balance-sheet optionality. Reassess after the next earnings release if attendance growth decelerates below industry box-office growth or margin expansion stalls.
• Establish a market-neutral long CNK / short AMC pair in equal dollar amounts over the next 1-3 months, particularly after AMC strength into major-release weekends. Thesis: AMC's capital-structure drag and dilution risk should outweigh its higher operating beta; exit if AMC demonstrates sustained positive free cash flow through a seasonally weak quarter without incremental equity issuance.
• Maintain or add IMAX on pullbacks for a 6-12 month premiumization thesis; installed-system growth and premium-screen mix can compound revenue per patron even if total attendance normalizes. Risk control: reduce if global premium-format box office materially lags broader box office for two consecutive quarters.
• Do not chase AMC outright following momentum-driven moves. Consider it only as a tactical long around verified release-slate strength, with a tight catalyst window and explicit monitoring of debt exchanges, at-the-market issuance, and quarterly cash conversion; these are more consequential to per-share value than a single-quarter EBITDA beat.